Optimization of PLGA formulation containing protein or peptide‐based antigen: Recent advances

Hajavi, Jafar; Ebrahimian, Mahboubeh; Sankian, Mojtaba; Khakzad, Mohammad Reza; Hashemi, Maryam

doi:10.1002/jbm.a.36423

Cited by 24 publications

(12 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some proteins are more sensible and need more sophisticated formulation systems for their stability. Usually, to increase the protein stability, stabilizers such as bovine serum albumin (BSA), succinylated gelatin or PEG are added to the water phase where protein solution is solubilized, to avoid protein degradation during the preparation process (Hajavi et al 2018 ; Panyam et al 2003 ; Van De Weert et al 2000 ). De Alteriis et al, successfully used BSA as protein stabilizer for vascular endothelial growth factor (VEGF) into PLGA MPs obtained by stamp-based method at room temperature exploiting solvent/non-solvent plasticization.…”

Section: Plga Mp Production Technique: Emulsification–evaporation Metmentioning

confidence: 99%

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

et al. 2020

View full text Add to dashboard Cite

Polymeric microparticles (MPs) are recognized as very popular carriers to increase the bioavailability and bio-distribution of both lipophilic and hydrophilic drugs. Among different kinds of polymers, poly-(lactic-co-glycolic acid) (PLGA) is one of the most accepted materials for this purpose, because of its biodegradability (due to the presence of ester linkages that are degraded by hydrolysis in aqueous environments) and safety (PLGA is a Food and Drug Administration (FDA)-approved compound). Moreover, its biodegradability depends on the number of glycolide units present in the structure, indeed, lower glycol content results in an increased degradation time and conversely a higher monomer unit number results in a decreased time. Due to this feature, it is possible to design and fabricate MPs with a programmable and time-controlled drug release. Many approaches and procedures can be used to prepare MPs. The chosen fabrication methodology influences size, stability, entrapment efficiency, and MPs release kinetics. For example, lipophilic drugs as chemotherapeutic agents (doxorubicin), anti-inflammatory non-steroidal (indomethacin), and nutraceuticals (curcumin) were successfully encapsulated in MPs prepared by single emulsion technique, while water-soluble compounds, such as aptamer, peptides and proteins, involved the use of double emulsion systems to provide a hydrophilic compartment and prevent molecular degradation. The purpose of this review is to provide an overview about the preparation and characterization of drug-loaded PLGA MPs obtained by single, double emulsion and microfluidic techniques, and their current applications in the pharmaceutical industry. Graphic abstract

show abstract

Section: Plga Mp Production Technique: Emulsification–evaporation Metmentioning

confidence: 99%

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nevertheless, several reports have shown that optimized processing protocols allow that proteins encapsulated into polymer matrices or grafted to polymer scaffolds may preserve their native conformation and thus their bioactivity for several months (31)(32). The permeability of protein therapeutics through barriers such as the skin, mucosal membranes and cellular membranes is substantially reduced due to high molecular mass, which leads to injection being the primary mode of administration (33).…”

Section: Limitations and Challengesmentioning

confidence: 99%

Polymer-Based Protein Delivery Systems for Loco-Regional Administration

Garcion¹,

Ramalapa²,

Buchtová³

et al. 2021

Green Synthesis in Nanomedicine and Human Health

View full text Add to dashboard Cite

With the advent of recombinant technology, a wide variety of biocompatible therapeutic proteins can be produced with relative ease. These proteins are formulated and subsequently administered in patients to treat various of diseases in a more effective and targeted manner. At the level of formulation development, protein molecules can be physically and/or chemically-conjugated to a wide array of naturally-occurring, semi-synthetic and synthetic biomaterials to form different types of protein delivery systems. Depending on their architecture and the extent of protein-scaffold interactions, these delivery systems can modify the pharmacokinetic and pharmacodynamic properties of the proteins. The versatility of polymer-based protein delivery systems such as micro/nanoparticles, hydrogels, porous scaffolds and fibrous scaffolds means it is possible to alter the spatial distribution of the protein load within the system as well as the protein release kinetics.These can then influence the ability of the protein molecules to exert their effects in their immediate microenvironments, be it to kill cancer cells or to recruit stem/progenitor cells. In this Chapter we discuss the production of protein therapeutics and the application of polymer-based biodegradable delivery systems for these proteins which include nanoparticles and scaffolds. We also include discussion of 'green synthesis' methods for production of these delivery systems.

show abstract

“…PLGA is approved by the FDA and European Medicines Agency in numerous drug transporter systems in humans (Prokop & Davidson, 2008). These NPs can act as delivery systems for trapping an antigen, mixing diverse antigens, or, more significantly, mixing adjuvants and antigens in the same particle (Hajavi, Ebrahimian, Sankian, Khakzad, & Hashemi, 2018). Furthermore, PLGA NPs, comprising very low doses of antigens and adjuvants, can stimulate robust T cell responses (Diwan, Elamanchili, Cao, & Samuel, 2004).…”

Section: Vector‐based or Particulate Delivery Systemmentioning

confidence: 99%

New and old adjuvants in allergen‐specific immunotherapy: With a focus on nanoparticles

Feng¹,

Yi²,

Hajavi

2020

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

Allergic diseases have remarkably increased in recent years. Nowadays, efforts for curing and management of these disorders are an important concern worldwide. Allergen-specific immunotherapy (ASIT) has recently gained more attention as a means for the management of allergic diseases. Adjuvants or helper agents are materials applied for better stimulating and shifting of protective responses, and these belong to an extremely diverse collection of complexes. The main function of adjuvants includes acting as depot foundations, transferring vehicles, and immunostimulators. Immunostimulatory adjuvants have gained increasing attention for ASIT. In this regard, the present study provides a review of old and new adjuvants used in allergen immunotherapy.

show abstract

Optimization of PLGA formulation containing protein or peptide‐based antigen: Recent advances

Cited by 24 publications

References 156 publications

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

Polymer-Based Protein Delivery Systems for Loco-Regional Administration

New and old adjuvants in allergen‐specific immunotherapy: With a focus on nanoparticles

Contact Info

Product

Resources

About